GLP-1 Myths and Misinformation: 14 Common Claims, Fact-Checked

GLP-1 medications became mainstream faster than the public discourse could keep up with the actual science. The result: a lot of misinformation. Some claims are exaggerated; some are out of context; some are simply wrong. This guide goes through the 14 most common claims you'll encounter — in social media, in WhatsApp forwards, in conversations with skeptical relatives — and what the actual evidence shows.

Each claim is rated: True, Partly true, False, or Not yet known.

Myth 1: "GLP-1 causes thyroid cancer"

Verdict: Not supported in humans. Precautionary boxed warning based on rodent studies.

The boxed warning on Ozempic, Wegovy, and Mounjaro derives from rodent studies (rats and mice) that showed C-cell tumours of the thyroid at high doses over long durations. Rodent thyroid C-cells behave differently from human C-cells, and the relevance to humans is debated.

Human evidence: Multiple large pharmacovigilance analyses (Bezin et al. 2023, Diabetes Care; FDA AERS post-marketing reviews) have not demonstrated a causal link between GLP-1 use and thyroid cancer in humans.

However: people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome should not take GLP-1 medications. This is an absolute contraindication, regardless of rodent vs human debate.

Myth 2: "GLP-1 causes depression and suicidal thoughts"

Verdict: Not supported by the evidence. Investigated, dismissed.

In 2023, post-marketing reports raised concern about depression and suicidal ideation in patients on GLP-1s. The FDA reviewed these reports in January 2024 and found no evidence of a causal link.

Independent large-scale studies have confirmed this:

• Wang et al. 2024 JAMA Internal Medicine — cohort analysis of 124,000 patients, no signal
• Schoretsanitis et al. 2024 JAMA Network Open — similar finding
• EMA (European Medicines Agency) 2024 review — same conclusion

If anything, GLP-1-driven weight loss is associated with improved mood in patients with subclinical depressive symptoms.

That said: any new or worsening mood changes on a GLP-1 should be reported to your doctor — true for any medication.

Myth 3: "GLP-1 just makes you lose muscle, not fat"

Verdict: Partly true — preventable with protein and resistance training.

Like any significant weight loss intervention (diet, surgery, fasting), GLP-1-driven weight loss includes some loss of lean mass alongside fat mass. Trial data suggests ~25 – 40% of weight lost is lean mass in patients who don't make active efforts to preserve muscle.

The fix is well-established:

• Protein intake 1.2 – 1.6 g/kg body weight daily preserves muscle during the calorie deficit
• Resistance training 2 – 3× per week signals to muscle that it's needed
• Adequate sleep
• Avoiding overly aggressive calorie restriction

In trials with protein and resistance training optimized, the muscle preservation is comparable to lifestyle-only weight loss. The "GLP-1 destroys muscle" framing is misleading — it's about how you support the medication, not the medication itself.

Myth 4: "Once you stop, the weight comes right back"

Verdict: True, if you stop abruptly without a transition plan.

This is real. The STEP-4 trial (Rubino et al., JAMA 2021) showed patients who switched from semaglutide to placebo regained two-thirds of lost weight within a year. SURMOUNT-4 (tirzepatide) showed the same pattern.

The reason: GLP-1 doesn't permanently change your body's weight regulation. It overrides hunger signals only while you're taking it. Your baseline physiology returns when the drug clears.

Implication: GLP-1 is best thought of as chronic-condition medication (like statins for cholesterol or ACE inhibitors for blood pressure). Most patients stay on long-term. Discontinuation, when appropriate, should be planned and gradual — not abrupt.

This doesn't mean "weight loss with GLP-1 isn't real" — it means "weight regulation requires ongoing management, not a one-time fix."

Myth 5: "It's the lazy person's shortcut"

Verdict: False, and rooted in obesity stigma.

Obesity is a chronic medical condition driven by complex genetics, hormones, metabolism, environment, and behaviour. Treating it with medication is medicine — not a shortcut.

We don't tell patients with hypertension that taking medication is "the lazy person's shortcut to lower blood pressure." We don't tell patients with diabetes that insulin is "cheating." The framing of obesity treatment as a moral issue rather than a medical one reflects outdated stigma, not science.

Patients on GLP-1 still have to:

• Modify diet
• Add or maintain physical activity
• Manage sleep
• Address mental health if relevant
• Attend follow-ups
• Manage side effects
• Continue lifelong health behaviours

The medication makes the calorie deficit achievable; everything else still requires effort.

Myth 6: "Compounded semaglutide from a spa or wellness clinic is the same thing"

Verdict: False, and often unsafe.

Compounded semaglutide (mixed by a compounding pharmacy rather than manufactured by Novo Nordisk) is not FDA-approved, not DCGI-approved, and not held to the same purity, sterility, and dose-accuracy standards as commercial Wegovy or Ozempic.

In the US, the FDA has issued multiple warnings about compounded semaglutide adverse events — including hospitalizations from dosing errors and contamination.

In India, legitimate generic semaglutide (post-March 2026 patent expiry) from licensed Indian pharma companies (Cipla, Sun Pharma, Dr Reddy's, Lupin, Biocon, etc.) is regulated and reliable. Compounded semaglutide from non-pharmaceutical sources is not the same thing — avoid.

Myth 7: "Indian generic semaglutide is fake or low-quality"

Verdict: False, when from licensed Indian pharma manufacturers.

India is one of the world's largest exporters of generic pharmaceuticals — supplying generics to the US, UK, EU, and over 100 other countries. Indian generic semaglutide from companies like Cipla, Sun Pharma, Dr Reddy's, Lupin, and Biocon is manufactured under CDSCO and (often) US FDA / EMA / WHO-prequalified standards.

The semaglutide molecule is the same. Bioavailability and clinical efficacy of generic semaglutide are expected to match branded.

Caveat: not all Indian semaglutide products are equal. Your doctor will recommend specific manufacturers with established track records. Buying from unverified online sources is unsafe regardless of branded vs generic.

Myth 8: "GLP-1 destroys your face — 'Ozempic face'"

Verdict: Partly true, but it's a feature of weight loss in general, not GLP-1 specifically.

"Ozempic face" — the gaunt look attributed to GLP-1 users — is actually a normal consequence of significant facial fat loss with weight loss. The face stores fat; when you lose body fat, your face changes too.

This happens with any weight loss method: dieting, surgery, GLP-1. It's not specific to medication.

What helps:

• Slower, more gradual weight loss
• Adequate protein intake to preserve facial muscle
• Adequate hydration
• Time for skin to adjust
• Skincare and sun protection

The framing of "Ozempic face" as a unique drug side effect is misleading — it's a feature of significant fat loss.

Myth 9: "GLP-1 causes pancreatitis"

Verdict: Small, monitored risk. Not an epidemic.

There is a known association between GLP-1 medications and pancreatitis — incidence in trials is small but slightly higher than placebo. Patients with a history of pancreatitis are usually not appropriate candidates.

The absolute numbers are small. The risk is monitored. Severe persistent abdominal pain on a GLP-1 should prompt immediate medical evaluation, but it doesn't happen often enough to be a reason not to consider the medication for an appropriate patient.

Myth 10: "GLP-1 causes gastroparesis"

Verdict: Mostly false (and confused with the intended slowed gastric emptying).

GLP-1 medications intentionally slow gastric emptying — that's how they make you feel full. This is dose-dependent and reversible.

Gastroparesis is a different clinical entity — severely delayed gastric emptying, often chronic, with vomiting, malnutrition, and inability to eat. True gastroparesis from GLP-1 is rare. Most reports are of normal medication-induced slowing being incorrectly labelled gastroparesis.

If GI symptoms are persistent and severe, your doctor evaluates — but the rate of true gastroparesis on GLP-1 is low.

Myth 11: "Generic semaglutide is unavailable in India"

Verdict: False as of March 20, 2026.

The Indian patent on semaglutide expired on March 20, 2026. At least 5 Indian pharmaceutical companies (Cipla, Sun Pharma, Dr Reddy's, Lupin, Biocon and others) have launched generic semaglutide at substantially lower prices than branded Wegovy / Ozempic.

The blanket claim that generic semaglutide is unavailable in India is outdated — though there's a separate question about quality and brand-specific recommendations (your doctor decides).

Tirzepatide (Mounjaro) is still patent-protected — no legal generics exist as of mid-2026.

Myth 12: "You can buy GLP-1 online without a prescription in India"

Verdict: True that some sources offer this. False that it's legal or safe.

It is illegal in India to dispense prescription-only medications (which all GLP-1 drugs are) without a valid prescription from a registered medical practitioner. Online sellers offering "no prescription needed" GLP-1 are:

• Operating illegally
• Frequently selling counterfeit product
• Often shipping cold-chain-failed product (GLP-1 pens require refrigeration)
• Bypassing medical screening for contraindications

The Telemedicine Practice Guidelines (2020) do allow prescription via video consultation — but that's a consultation with a registered Indian doctor, not "fill out a form and we ship it."

Myth 13: "GLP-1 is only for diabetes"

Verdict: Historically true; no longer true.

GLP-1 medications were first developed for type 2 diabetes (exenatide approved 2005). The discovery that they also produced significant weight loss in non-diabetic patients led to weight-management-specific dose approvals:

• Saxenda (liraglutide 3.0 mg) for obesity: 2014 (FDA)
• Wegovy (semaglutide 2.4 mg) for obesity: 2021 (FDA), 2025 (India)
• Zepbound / Mounjaro (tirzepatide) for obesity: 2023 (FDA), 2025 (India)

In 2026, chronic weight management is one of the two principal indications for GLP-1 medications — alongside type 2 diabetes. The "only for diabetes" framing is two decades out of date.

Myth 14: "If GLP-1s worked, doctors would prescribe them to everyone"

Verdict: False — they're prescribed for appropriate patients, and appropriate patients don't include everyone.

GLP-1 medications are indicated for:

• Adults with BMI ≥ 30 (obesity), or
• Adults with BMI ≥ 27 (overweight) with at least one weight-related comorbidity

They are contraindicated for:

• Personal/family history of medullary thyroid carcinoma or MEN2 syndrome
• History of severe pancreatitis
• Severe gastrointestinal disease
• Pregnancy / breastfeeding / planning pregnancy in next 2 months
• Patients with type 1 diabetes (off-label only with specialist oversight)
• Patients with active eating disorders
• Some specific medication combinations

The reason your friend on Mounjaro lost 18 kg and your colleague's doctor wouldn't prescribe it for them is medical eligibility, not medical hesitance.

Bonus: misinformation that comes from real concerns but gets exaggerated

• "GLP-1 weight loss is unsustainable" — true if you stop the medication abruptly without a plan; false if maintained or transitioned properly.
• "GLP-1 makes you feel sick all the time" — true during titration weeks; false at maintenance dose for most patients with appropriate titration management.
• "It's just water weight" — false. Early loss includes some water/glycogen depletion (any rapid weight loss does), but the sustained loss after month 2 is overwhelmingly fat mass.
• "It's a fad" — false. GLP-1 medications have ~20 years of post-marketing data starting from exenatide in 2005. They're a well-established drug class, not a trend.

How Stride handles misinformation

Patients come to Stride with a lot of half-true information. Part of the care-team's job is medical literacy — explaining what's accurate, what's exaggerated, what's contested. Your doctor's consultation is the place for this conversation — not WhatsApp forwards or Instagram videos.

3-Month Early Edition: ₹9,999 (regular ₹23,999). Doctor consultations include time for any questions about the medication.

Frequently asked questions

Where does GLP-1 misinformation typically come from? Three sources: pre-2020 outdated framing (when GLP-1 was niche diabetes medication), legitimate concerns exaggerated out of context (rodent thyroid signal, isolated mood reports), and commercial interests on either side (people selling alternatives, or people pushing the medication for inappropriate populations).

How do I evaluate a claim I see on social media? Check: Is there a citation? Is the citation a peer-reviewed paper or a press release? Is the claim consistent with mainstream medical guidance (e.g., FDA, EMA, Indian medical bodies)? Does the source have a financial conflict of interest? Most viral GLP-1 claims fail at least one of these tests.

Are there real concerns I should know about? Yes — see myths 1, 3, 4, 9 specifically. Real concerns exist around contraindications, weight regain after discontinuation, muscle loss without protein support, and rare side effects. These are well-managed by appropriate medical care.

Should I share this post with my skeptical relatives? Sure, but no link will overcome long-held beliefs. The most effective response to misinformation is usually personal experience under medical supervision — show, don't argue.

Ready to start with informed, evidence-based care?

Check your eligibility — Stride's consultations include time for your specific questions about the medication.